Risk Reduction
Conditions
Keywords
PrEP, Young MSM, POC monitoring, adherence, motivational interviewing, urine test, tenofovir
Brief summary
Despite advances in HIV prevention, the HIV incidence among young men who have sex with men (YMSM) is increasing, threatening to derail achievement of the United States End the HIV Epidemic goals. Although, pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention method, adherence was sufficiently low to comprise efficacy among a high proportion of YMSM in multiple clinical trials and demonstration projects. In this study, the investigators will leverage a novel urine point-of-care drug-level test for PrEP adherence, to both enhance and target motivational-interviewing-based adherence counseling among YMSM, with the goal of preventing HIV infections among this critically at-risk group.
Detailed description
Young men who have sex with men (YMSM; ages 15-29 years) have rising HIV incidence in the United States. Pre-exposure prophylaxis (PrEP) is a highly effective medication prevent HIV infection, both at the individual and population level. However, in several clinical trials and demonstration projects among YMSM, a majority of participants had adherence to PrEP sufficiently low to compromise efficacy throughout the study. Unfortunately, pill-counts and self-reported adherence have limitations in this population, and therapeutic drug monitoring using previously available methods requires expensive equipment and specialized staff, meaning it cannot be implemented at the point-of-care (POC). The investigators have developed a novel POC test to measure urine drug-levels to PrEP for the first time, providing the opportunity to target and enhance adherence counseling during a routine clinical visit. Substantial knowledge gaps on the correct counseling approach and framing of the drug-level feedback message must be addressed to use this strategy to improve adherence among YMSM. This study will use a mixed methods approach to test the central hypothesis that an intervention leveraging a POC urine bioassay to detect PrEP adherence can both target and enhance adherence counseling. Brief interventions are a motivational interviewing (MI) counseling approach with wide uptake by primary care providers for substance use prevention and medical therapy adherence. PrEP2-BAY proposes a brief intervention be used as the framework for POC drug-level feedback among YMSM using PrEP. This study will test the acceptability, feasibility, and preliminary impact on long-term adherence, measured through hair tenofovir levels, of the brief intervention in a pilot randomized controlled trial among YMSM. This proposed research plan has the goal of optimizing PrEP's impact through a novel adherence support intervention. The findings of this proposal will lead to a R01 application to test a POC bioassay-enhanced adherence brief intervention among YMSM in a multi-city trial, with the goal of reducing the burden of HIV among MSM.
Interventions
Motivational interviewing-based counseling will be provided to the participant based on the results of the urine test
Urine will be collected and the presence or absence of tenofovir will be measured with the point-of-care urine tenofovir test.
Sponsors
Study design
Eligibility
Inclusion criteria
* Male sex at birth who has sex with men * Age 18-30 years-old * Currently receiving tenofovir-based oral PrEP * Plans to continue taking daily PrEP over the upcoming 3 months
Exclusion criteria
* Participant living with HIV * Age \> 30 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Indicating the Intervention Was Acceptable | 3 months | Number of participants reporting the intervention to be "somewhat" or "very" acceptable on a five-point Likert scale |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Long-term Adherence Outcomes | 3 months | Measure change in tenofovir levels in hair samples from baseline to 3 months using liquid chromatography-mass spectrometry assays. |
Countries
United States
Contacts
University of California, San Francisco
Participant flow
Recruitment details
Participants were recruited via targeted advertisements on a geospatial social mobile application.
Pre-assignment details
63 participants were enrolled and randomized.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 26.1 Years STANDARD_DEVIATION 2.7 |
| Daily PrEP Regimen Descovy (FTC/TAF) | 8 Participants |
| Daily PrEP Regimen Truvada (FTC/TDF) | 32 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 14 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 39 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants |
| Race (NIH/OMB) Asian | 8 Participants |
| Race (NIH/OMB) Black or African American | 5 Participants |
| Race (NIH/OMB) More than one race | 5 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 23 Participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 20 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 42 | 0 / 21 |
| other Total, other adverse events | 0 / 42 | 0 / 21 |
| serious Total, serious adverse events | 0 / 42 | 0 / 21 |